October 14, 2020 – Thermo Fisher Scientific Inc. (Waltham, MA) announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia-Pacific region for the development and manufacture of therapies and vaccines.
The $130 million facility will be operated by Thermo Fisher and have the capability to manufacture pharmaceutical products to meet demand in the region and respond effectively to future health emergencies, the company says.
The new facility will initially include a high-speed sterile line approved for live virus filling – the first such large scale capability in Singapore – followed by an additional line for standard fill/finish.
The facility will also have cleanroom capacity, labs, warehousing and offices to support production. Once operational in 2022, the facility could manufacture up to 30 million sterile doses per month and employ more than 300 people, Thermo Fisher Scientific says.